CORTINOVIS DIEGO LUIGI

Pubblicazioni

  • Vigliar, E., Malapelle, U., Bono, F., Fusco, N., Cortinovis, D., Valtorta, E., et al. (2019). The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. BIOMED RESEARCH INTERNATIONAL, 2019, 7. Dettaglio
  • Giordano, F., Vaira, V., Cortinovis, D., Bonomo, S., Goedmakers, J., Brena, F., et al. (2019). p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 38(1). Dettaglio
  • Sharma, G., Cortinovis, D., Agustoni, F., Arosio, G., Villa, M., Cordani, N., et al. (2019). A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. JOURNAL OF THORACIC ONCOLOGY, 14(11), e257-e259. Dettaglio
  • Alberti, P., Rossi, E., Argyriou, A., Kalofonos, H., Briani, C., Cacciavillani, M., et al. (2018). RISK STRATIFICATION OF OXALIPLATIN INDUCED PERIPHERAL NEUROTOXICITY APPLYING ELECTROPHYSIOLOGICAL TESTING OF DORSAL SURAL NERVE. SUPPORTIVE CARE IN CANCER. Dettaglio
  • Kieffer, J., Postma, T., van de Poll Franse, L., Mols, F., Heimans, J., Cavaletti, G., et al. (2017). Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20). QUALITY OF LIFE RESEARCH, 1-12. Dettaglio